Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Verastem stock | 1.52

Own Verastem stock in just a few minutes.


Fact checked

Verastem, Inc is a biotechnology business based in the US. Verastem shares (VSTM) are listed on the NASDAQ and all prices are listed in US Dollars. Verastem employs 135 staff and has a trailing 12-month revenue of around USD$21.6 million.

How to buy shares in Verastem

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Verastem. Find the stock by name or ticker symbol: VSTM. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Verastem reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$1.52, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Verastem, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Verastem. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Verastem's share price?

Since the stock market crash in March caused by coronavirus, Verastem's share price has had significant negative movement.

Its last market close was USD$1.52, which is 30.28% down on its pre-crash value of USD$2.18 and 1.33% up on the lowest point reached during the March crash when the shares fell as low as USD$1.5.

If you had bought USD$1,000 worth of Verastem shares at the start of February 2020, those shares would have been worth USD$1,053.18 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$808.50.

Verastem share price

Use our graph to track the performance of VSTM stocks over time.

Verastem shares at a glance

Information last updated 2020-11-25.
Latest market close USD$1.52
52-week range USD$1.08 - USD$4.6699
50-day moving average USD$1.3369
200-day moving average USD$1.4801
Wall St. target price USD$3.83
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.844

Buy Verastem shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Stocks, Mutual funds, ETFs, Forex
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Verastem stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Verastem price performance over time

Historical closes compared with the close of $1.52 from 2020-11-16

1 week (2020-11-19) N/A
1 month (2020-10-30) 26.67%
3 months (2020-08-26) N/A
6 months (2020-05-26) N/A
1 year (2019-11-26) N/A
2 years (2018-11-26) N/A
3 years (2017-11-26) N/A
5 years (2015-11-26) N/A

Verastem financials

Revenue TTM USD$21.6 million
Gross profit TTM USD$16.2 million
Return on assets TTM -39.94%
Return on equity TTM -114.53%
Profit margin 0%
Book value $0.765
Market capitalisation USD$288.6 million

TTM: trailing 12 months

Shorting Verastem shares

There are currently 5.7 million Verastem shares held short by investors – that's known as Verastem's "short interest". This figure is 4.1% up from 5.5 million last month.

There are a few different ways that this level of interest in shorting Verastem shares can be evaluated.

Verastem's "short interest ratio" (SIR)

Verastem's "short interest ratio" (SIR) is the quantity of Verastem shares currently shorted divided by the average quantity of Verastem shares traded daily (recently around 2.3 million). Verastem's SIR currently stands at 2.46. In other words for every 100,000 Verastem shares traded daily on the market, roughly 2460 shares are currently held short.

However Verastem's short interest can also be evaluated against the total number of Verastem shares, or, against the total number of tradable Verastem shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Verastem's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Verastem shares in existence, roughly 30 shares are currently held short) or 0.0374% of the tradable shares (for every 100,000 tradable Verastem shares, roughly 37 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Verastem.

Find out more about how you can short Verastem stock.

Verastem share dividends

We're not expecting Verastem to pay a dividend over the next 12 months.

Verastem share price volatility

Over the last 12 months, Verastem's shares have ranged in value from as little as $1.08 up to $4.6699. A popular way to gauge a stock's volatility is its "beta".

VSTM.US volatility(beta: 0.77)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Verastem's is 0.7711. This would suggest that Verastem's shares are less volatile than average (for this exchange).

Verastem overview

Verastem, Inc., a biopharmaceutical company, focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The indication in FL is approved under accelerated approval based on overall response rate. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being investigated in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), mesothelioma, and other solid tumors. Verastem, Inc. has collaboration agreements with Yakult Honsha Co., Ltd. and CSPC Pharmaceutical Group Limited. The company was founded in 2010 and is based in Needham, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site